Action ATORX ALLIGATOR BIOSCIENCE AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Alligator Bioscience AB

Actions

ATORX

SE0000767188

Marché Fermé - Nasdaq Stockholm
Autres places de cotation
 18:00:00 10/06/2024 		Varia. 5j. Varia. 1 janv.
1,11 SEK -3,98 % Graphique intraday de Alligator Bioscience AB -1,94 % +61,10 %
03/06 Alligator Bioscience annonce la publication des résultats positifs de la phase 2 de son principal candidat-médicament, le mitazalimab, dans le traitement de première intention du cancer du pancréas métastatique dans le Lancet Oncology. CI
23/05 Alligator Bioscience présentera des données positives de phase 2 sur le mitazalimab dans le cancer du pancréas lors de la réunion annuelle de l'ASCO en 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
BioStock: Alligator's mitazalimab data published in The Lancet Oncology
Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology
Alligator Bioscience Announces Publication of on Its Lead Drug Candidate Positive Phase 2 Data Mitazalimab in First Line Metastatic Pancreatic Cancer in the Lancet Oncology
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial
Alligator Bioscience : Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer
Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer
Alligator Bioscience : Announces Publication Highlighting Potential of Next Generation CD40 Agonists in Peer Reviewed Medical Journal "Expert Opinion on Biological Therapy"
Alligator Bioscience Announces Publication Highlighting Potential of Next-Generation CD40 Agonists in Peer-Reviewed Medical Journal "Expert Opinion on Biological Therapy"
Alligator Bioscience Announces Initiation of an Investigator-Initiated Initiation of Phase 1 Clinical Study of Intratumoral Mitazalimab in Locally Advanced Pancreatic Cancer
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer
Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2024
Alligator Bioscience Q1 2024 - The Next Catalyst Will Be the 18-month Readout
Alligator Bioscience AB reports financial results for Q1 2024 and provides a business update
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024
BioStock: Orion option exercise triggers milestone payment for Alligator
Change in number of shares and votes in Alligator Bioscience AB
Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ATORX
  4. Actualités Alligator Bioscience AB
  5. Autres langues